Overview
OPTH market data
Price History
OPTH price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for OPTH. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant DepressionGlobenewswire Inc · Jun 29, 2026, 1:15 PM
Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025Benzinga · Jun 29, 2026, 1:10 PM
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and AssetsBenzinga · Jun 18, 2026, 1:15 PM
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical ResearchBenzinga · Jun 16, 2026, 5:15 PM
Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research OrganizationsBenzinga · Jun 16, 2026, 12:40 PM
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaBenzinga · Jun 2, 2026, 5:15 PM
SRx Health Solutions Invests In Optimi Health To Tap Into Psychedelic Industry; Amounts Not DisclosedBenzinga · May 21, 2026, 1:10 PM
Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/ShrBenzinga · May 20, 2026, 3:40 PM
Trading Halt: Halt status updated at 9:50:00 AM ET: Quotation Resumption: IPO Security - Released for QuotationBenzinga · May 20, 2026, 1:55 PM